Clinical Trials · NCT00313183

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus

Name: A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Pramlintide

Phase: Phase 2
Recruitment status: Completed
Sponsor: AstraZeneca
Enrollment: 12
Start date: Apr 2006
Locations: 3 sites, United States
Primary endpoint: To evaluate the pharmacokinetics of Symlin in adolescent subjects with type 1 diabetes

View Pramlintide compound reference